Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Tr1X logo — Engineering cures for patients with autoimmune & inflammator...

Tr1X

Engineering cures for patients with autoimmune & inflammatory diseases.

Founded 2018 United States San Diego, United States 46 employees Unknown Total: $125.00M Biotechnology, Health Care +1

General Information

Company Name Tr1X
Founded Year 2018
Location United States San Diego, United States +1
Employees 46
Industries Biotechnology, Health Care, Life Sciences
Funding Stage Unknown
Social

Get notified when Tr1X moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Tr1X

Tr1X Inc. is a biotechnology company founded in 2018, with headquarters in La Jolla, CA. The company's slogan "Engineering cures for patients with autoimmune & inflammatory diseases" encapsulates its dedication to developing novel cellular immunotherapies for patients in need. Tr1X specializes in leveraging its proprietary platform to generate first-in-class cell therapy products aimed at rebalancing the immune system and restoring homeostasis, thus leading to long-term tolerance. As of 17 January 2024, the company secured a significant $75.00M Series A investment led by notable investors including The Column Group, Alexandria Venture Investments, and Neva SGR. Tr1X operates within the Biotechnology and Health Care industries and shows promise in addressing unmet medical needs within the autoimmune and inflammatory disease space, making it a compelling investment prospect for venture capitalists seeking to support groundbreaking therapeutic advancements.

Taxonomy: cellular immunotherapies, autoimmune diseases, inflammatory diseases, immune system, cell therapy, proprietary platform, immune modulation, homeostasis, tolerance, La Jolla, California

Funding Rounds & Investors (3)

View All
Funding Stage Amount Investors Lead Investors Date
Early VC •••••• - 01 Oct 2025
Series A •••••• 3
Investor Investor Investor
01 Jan 2024
Spinout •••••• 1 •••• •••• 01 Jan 2018

Tr1X Alternatives & Competitors

Tr1X vs
Cellenkos, Inc.
Cellenkos, Inc.

Developing off-the-shelf T regulatory (Treg) cell therapies for rare inflammatory diseases and autoi...

Series A
14 employees
Biotechnology
Compare Tr1X vs Cellenkos, Inc.
Tr1X vs
GentiBio
GentiBio United States

𝗪𝗲 𝗺𝗮𝗸𝗲 𝗧𝗿𝗲𝗴𝘀. 𝘽𝙚𝙩𝙩𝙚𝙧.

43 employees
Tr1X vs
Sonoma Biotherapeutics, Inc.
Sonoma Biotherapeutics, Inc. United States

Leading the Next Frontier of Cell Therapy

Corporate Round
65 employees
Biotechnology, Health and Wellness
Compare Tr1X vs Sonoma Biotherapeutics, Inc.
Also compare with: Tr1X vs AbolerIS Pharma AbolerIS Pharma

FAQ About Tr1X

Engineering cures for patients with autoimmune & inflammatory diseases.
Tr1X was founded in 2018.
Tr1X is headquartered in San Diego, United States.
Tr1X operates in the following industries: Biotechnology, Health Care, Life Sciences.
Tr1X has approximately 46 employees.
Tr1X has completed 3 funding rounds, raising a total of $125.00M. The latest funding stage is Unknown.
Top alternatives and competitors to Tr1X include Cellenkos, Inc., GentiBio, Sonoma Biotherapeutics, Inc., AbolerIS Pharma, Adicet Bio, Inc. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Tr1X and Cellenkos, Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Tr1X and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy